References
- BannisterKKucharczykMDickensonAHHopes for the future of pain controlPain Ther20176211712828536900
- ZajączkowskaRPrzewłockaBKocot-KępskaMMikaJLeppertWWordliczekJTapentadol – A representative of a new class of MOR-NRI analgesicsPharmacol Rep201870481282029921501
- TzschentkeTMChristophTKögelBYThe mu-opioid receptor agonist/noradrenaline reuptake inhibition (MOR-NRI) concept in analgesia: the case of tapentadolCNS Drugs201428431932924578192
- TzschentkeTMChristophTKögelB(-)-(1R,2R)-3-(3-dimeth-ylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic propertiesJ Pharmacol Exp Ther2007323126527617656655
- LangfordRMKnaggsRFarquhar-SmithPDickensonAHIs tapen-tadol different from classical opioids? A review of the evidenceBr J Pain201610421722127867511
- BannisterKPatelRGoncalvesLTownsonLDickensonAHDiffuse noxious inhibitory controls and nerve injury: restoring an imbalance between descending monoamine inhibitions and facilitationsPain201515691803181126010460
- KressHGTapentadol and its two mechanisms of action: is there a new pharmacological class of centrally-acting analgesics on the horizon?Eur J Pain201014878178320659810
- RaffaRBEllingCTzschentkeTMDoes ‘Strong Analgesic’ Equal ‘Strong Opioid’? Tapentadol and the Concept of ‘µ-Load’Adv Ther20181471148430206823
- PergolizziJVJrLequangJATaylorROssipovMHColucciDRaffaRBDesigning safer analgesics: a focus on µ-opioid receptor pathwaysExpert Opin Drug Discov2018131096597230175624
- Vargas-SchafferGIs the WHO analgesic ladder still valid? Twenty-four years of experienceCan Fam Physician201056651451520547511
- TzschentkeTMDe VryJTerlindenRTapentadol hydrochloride. Analgesic, mu-opioid receptor agonist, noradrenaline reuptake inhibitorDrugs Future20063110531061
- TzschentkeTMJahnelUKogelBTapentadol hydrochloride: a next-generation, centrally acting analgesic with two mechanisms of action in a single moleculeDrugs Today200945748349619834626
- RinonapoliGCoaccioliSPanellaLTapentadol in the treatment of osteoarthritis: pharmacological rationale and clinical evidenceJ Pain Res2019
- PolatiEDel BalzoGMartiniAMatteoTSchweigerVCollinoMTapentadol: an overview of the safety profileJ Pain Res2019
- ColuzziFPolatiEFreoUGrilliMTapentadol: an effective option for the treatment of back painJ Pain Res2019
- RomualdiPKressHGFreoUTapentadol prolonged release for neuropathic pain: a review clinical studiesJ Pain Res2019
- MandalàMMoroCLabiancaRCremonesiMBarniSOptimizing use of opiates in the management of cancer painTher Clin Risk Manag20062444745318360655
- DroneyJRileyJRecent advances in the use of opioids for cancer painJ Pain Res2009213515521197301
- CaraceniAHanksGKaasaSUse of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPCLancet Oncol2012132e58e6822300860
- KressHGKochEDKosturskiHTapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related painPain Physician201417432934325054392
- ImanakaKTominagaYEtropolskiMEfficacy and safety of oral tapentadol extended release in Japanese and Korean patients with moderate to severe, chronic malignant tumor-related painCurr Med Res Opin201329101399140923937387
- KressHGColuzziFTapentadol in the management of cancer pain: current evidence and future perspectivesJ Pain Res2019